Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RESERP versus SERPASIL ESIDRIX 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RESERP versus SERPASIL ESIDRIX 2.
HYDRO-RESERP vs SERPASIL-ESIDRIX #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
None Documented
None Documented
50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing.
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites.
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination